Advertisement

European Journal of Applied Physiology

, Volume 111, Issue 8, pp 1929–1938 | Cite as

Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin

  • Fayçal Meziri
  • Delphine Binda
  • Sabeur Touati
  • Maxime Pellegrin
  • Alain Berthelot
  • Rhian M. Touyz
  • Pascal Laurant
Original Article

Abstract

Chronic administration of recombinant human erythropoietin (rHuEPO) can generate serious cardiovascular side effects such as arterial hypertension (HTA) in clinical and sport fields. It is hypothesized that nitric oxide (NO) can protect from noxious cardiovascular effects induced by chronic administration of rHuEPO. On this base, we studied the cardiovascular effects of chronic administration of rHuEPO in exercise-trained rats treated with an inhibitor of NO synthesis (L-NAME). Rats were treated or not with rHuEPO and/or L-NAME during 6 weeks. During the same period, rats were subjected to treadmill exercise. The blood pressure was measured weekly. Endothelial function of isolated aorta and small mesenteric arteries were studied and the morphology of the latter was investigated. L-NAME induced hypertension (197 ± 6 mmHg, at the end of the protocol). Exercise prevented the rise in blood pressure induced by L-NAME (170 ± 5 mmHg). However, exercise-trained rats treated with both rHuEPO and L-NAME developed severe hypertension (228 ± 9 mmHg). Furthermore, in these exercise-trained rats treated with rHuEPO/L-NAME, the acetylcholine-induced relaxation was markedly impaired in isolated aorta (60% of maximal relaxation) and small mesenteric arteries (53%). L-NAME hypertension induced an internal remodeling of small mesenteric arteries that was not modified by exercise, rHuEPO or both. Vascular ET-1 production was not increased in rHuEPO/L-NAME/training hypertensive rats. Furthermore, we observed that rHuEPO/L-NAME/training hypertensive rats died during the exercise or the recovery period (mortality 51%). Our findings suggest that the use of rHuEPO in sport, in order to improve physical performance, represents a high and fatal risk factor, especially with pre-existing cardiovascular risk.

Keywords

Hypertension Exercise Doping Endothelial dysfunction 

Notes

Acknowledgments

The authors thank Isabelle Jallat and Manuel Gil for technical assistance.

Conflict of interest

The other authors report no conflicts.

References

  1. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91:3974–3978PubMedCrossRefGoogle Scholar
  2. Berglund B, Ekblom B (1991) Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 229:125–130PubMedCrossRefGoogle Scholar
  3. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M (1993) Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43:1010–1014PubMedCrossRefGoogle Scholar
  4. De Moraes C, Davel AP, Rossoni LV, Antunes E, Zanesco A (2008) Exercise training improves relaxation response and SOD-1 expression in aortic and mesenteric rings from high caloric diet-fed rats. BMC Physiol 29(8):12CrossRefGoogle Scholar
  5. Depping R, Kawakami K, Ocker H, Wagner JM, Heringlake M, Noetzold A, Sievers HH, Wagner KF (2005) Expression of the erythropoietin receptor in human heart. J Thorax Cardiovasc Surg 130:872–877Google Scholar
  6. Duncker DJ, Bache RJ (2008) Regulation of coronary blood flow during exercise. Physiol Rev 88:1009–1086PubMedCrossRefGoogle Scholar
  7. El-Sayed MS, Ali N, El-Sayed Ali Z (2005) Haemorheology in exercise and training. Sports Med 35:649–670PubMedCrossRefGoogle Scholar
  8. Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW (1989) USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Contrib Nephrol 76:160–165PubMedGoogle Scholar
  9. Franke WD, Stephens GM, Schmid PG (1998) Effect of intense exercise training on endothelium-dependent exercise induced vasodilatation. Clin Physiol 18:521–528PubMedCrossRefGoogle Scholar
  10. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G (1998) Regular physical exercise correct endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 98:2709–2715PubMedGoogle Scholar
  11. Heylen E, Guerrero F, Mansourati J, Theron M, Thioub S, Saïag B (2008) Effect of training frequency on endothelium-dependnet vasorelaxation in rats. Eur J Cardiovasc Prev Rehabil 15(1):52–58PubMedCrossRefGoogle Scholar
  12. Jasperse JL, Laughlin MH (2006) Endothelial function and exercise training; evidence from studies using animal models. Med Sci Sports Exerc 38:445–454PubMedCrossRefGoogle Scholar
  13. Katoh K, Mizuno K, Hashimoto S, Okasaki K, Asahi K, Kuriki M, Yamada D, Fukuchi S (1994) Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 54:253–259CrossRefGoogle Scholar
  14. Kemi OJ, Wisloff U (2010) High-intensity aerobic exercise training improves the heart in health and disease. J Cardiopulm Rehabil Prev 30(1):2–11PubMedGoogle Scholar
  15. Kuchan MJ, Frangos JA (1993) Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 264:H150–H156PubMedGoogle Scholar
  16. Kuru O, Sentürk UK, Koçer G, Ozdem S, Başkurt OK, Cetin A, Yeşilkaya A, Gündüz F (2009) Effect of exercise training on resistance arteries in rats with chronic NOS inhibition. J Appl Physiol 107(3):896–902PubMedCrossRefGoogle Scholar
  17. Lacasse MS, Kingma I, Larivière R, Grose JH, Lebel M (1997) Uremia enhances the blood pressure response to erythropoietin. Clin Exp Hypertens 19:389–401CrossRefGoogle Scholar
  18. Laurant P, Touyz RM, Schiffrin EL (1997) Effect of pressurization on mechanical properties of mesenteric small arteries from spontaneously hypertensive rats. J Vasc Res 34(2):117–125PubMedCrossRefGoogle Scholar
  19. Leung FP, Yung LM, Laher I, Yao X, Chen ZY, Huang Y (2008) Exercise, vascular wall and cardiovascular diseases: an update (part 1). Sports Med 38(12):1009–1024PubMedCrossRefGoogle Scholar
  20. Maiorana A, O’Driscoll G, Taylor R, Green D (2003) Exercise and the nitric oxide vasodilator system. Sports Med 33:1013–1035PubMedCrossRefGoogle Scholar
  21. Maschio G (1995) Erythropoietin and systemic hypertension. Nephrol Dial Transplant 10:74–79PubMedGoogle Scholar
  22. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F (2000) Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11:335–342PubMedGoogle Scholar
  23. Mulvany MJ (1999) Vascular remodelling of resistance vessels: can we define this? Cardiovasc Res 41:9–13PubMedCrossRefGoogle Scholar
  24. Nagai T, Akizawa T, Nakashima Y, Kohjiro S, Nabeshima K, Kanamori N, Takayama K, Kinugasa E, Koshikawa S (1995) Effects of rHuEPO on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 10:1814–1819PubMedGoogle Scholar
  25. Quasching T, Ruschitzka F, Stallmach T, Shaw S, Morawietz H, Goettsch W, Hermann M, Slowinski T, Theuring F, Hocher B, Lüscher TF, Gassman M (2002) Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J 97:11609–11613Google Scholar
  26. Ramotar JE (1990) Cyclists’ deaths linked to erythropoietin? Phys Sportsmed 18:48–50Google Scholar
  27. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K, Labugger R, Kelm M, Noll G, Rulicke T, Shaw S, Lindberg RL, Rodenwaldt B, Lutz H, Bauer C, Luscher TF, Gassmann M (2000) Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97:11609–11613PubMedCrossRefGoogle Scholar
  28. Schächinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101(16):1899–1906PubMedGoogle Scholar
  29. Schiffl H, Lang SM (1997) Hypertension induced by recombinant human erythropoietin (rHuEPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calcium. Eur J Med Research 2:97–100Google Scholar
  30. Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548PubMedCrossRefGoogle Scholar
  31. Srere PA (1969) Citrate synthase. Methods Enzymol 13:3–5CrossRefGoogle Scholar
  32. Todorov V, Gess B, Gödecke A, Wagner C, Schräder J, Kurtz A (2000) Endogenous nitric oxide attenuates erythropoietin gene expression in vivo. Pflüg Arch 439:445–448CrossRefGoogle Scholar
  33. Tsukahara H, Hori C, Hiraoka M, Mayumi M, Okada T, Gejyo F (1997) Nitric oxide modulation of erythropoiesis in rats. Blood 90:473–474PubMedGoogle Scholar
  34. Walsh JH, Bilsborough W, Maiorana A, Best M, O’Driscoll GJ, Taylor RR, Green DJ (2003) Exercise training improves conduit vessel function in patients with coronary artery disease. J Appl Physiol 285:20–25Google Scholar
  35. Wang XQ, Vaziri ND (1999) Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33:894–899PubMedGoogle Scholar
  36. Yang HT, Ren J, Laughlin MH, Terjung RL (2002) Prior exercise training produces NO-dependent increases in collateral blood flow after acute arterial occlusion. Am J Physiol 282:301–310Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Fayçal Meziri
    • 1
    • 4
  • Delphine Binda
    • 2
  • Sabeur Touati
    • 1
  • Maxime Pellegrin
    • 2
  • Alain Berthelot
    • 2
  • Rhian M. Touyz
    • 3
  • Pascal Laurant
    • 1
  1. 1.EA4278 Physiology and Physiopathology of Cardiovascular Adaptations to Exercise, Faculty of SciencesUniversity of AvignonAvignonFrance
  2. 2.EA4267 2SBPUFR SMPBesançonFrance
  3. 3.Kidney Research Centre, Ottawa Health Research InstituteUniversity of OttawaOttawaCanada
  4. 4.EA4278 Physiologie et Physiopathologie des Adaptations Cardiovasculaires et à l’ExercicePôle Sportif et de Recherche UniversitaireAvignonFrance

Personalised recommendations